fda warning bpc-157 unapproved drug safety concerns Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling Advisers to the FDA back

Advisers to the FDA back broad access to unapproved peptides, despite agency concerns FDA Issues Warning: Compounding Certain Bulk Drug Substances May Pose Major Legal and Patient Safety Risks Lengea BPC 157 Legal Status: FDA Regulations and Compounding Health advisers begin meeting Thursday to review more than a half dozen peptides, unproven substances that have become a growing wellness trend despite little evidence they are safe or effective. Full story

SKU: 76030146868 · From iglepidom.org